Arbutus Biopharma Corp (ABUS) financials
Arbutus Biopharma revenue and earnings by year
Arbutus Biopharma's revenue was $14.1 million in the fiscal year to December 31, 2025, up 128.2% from the year before. Net income was -$33.5 million, -237.9% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 28.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 6 | 18 | 39 | 11 | 7 | 6 | 6 | 11 | 1 |
| Revenue growth | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | 15.0% | 1.1% | -44.4% | 617.6% | — |
| Operating income | -40 | -74 | -78 | -63 | -72 | -57 | -144 | -90 | -111 | -492 |
| Operating margin | -284.0% | -1194.2% | -430.2% | -162.0% | -652.1% | -829.2% | -2396.8% | -1510.2% | -1036.7% | -32973.8% |
| Net income | -34 | -70 | -73 | -69 | -76 | -64 | -154 | -57 | -84 | -384 |
| Net margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | -2557.4% | -959.8% | -788.9% | -25765.5% |
| Diluted EPS | -$0.17 | -$0.38 | -$0.44 | -$0.46 | -$0.83 | -$1.00 | -$2.89 | -$1.22 | -$1.55 | -$7.24 |
| Free cash flow | -40 | -65 | -87 | -36 | -68 | -52 | -72 | -69 | -56 | -62 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ABUS in Markets.
How Arbutus Biopharma makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| License | $632K | 62.3% |
| Collaboration & Contracts | $202K | 19.9% |
| Non Cash Royalty | $180K | 17.8% |
See also: ABUS valuation and P/E history · ABUS returns
No forecast, no recommendation. This page describes Arbutus Biopharma Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.